Skip to main content

Preclinical Proof-Of-Concept

ERBC works hand in hand with academic and industrial partners during the early stages of drug development to demonstrate the preclinical proof-of-concept of the test compound, ultimately aiming to convert it into a drug candidate.

ERBC performs a range in vivo assays and offers numerous animal models of human diseases covering almost all therapeutic areas.

At ERBC, we consider this initial step of in vivo proof-of-concept studies as essential to minimize risks of late attrition during clinical trials reminding that the lack of efficacy in the clinic is one of first cause of late attrition during drug development. ERBC offers the clear advantage to run these pivotal studies under GLP (Good Laboratory Practice).

GLP certified
our expertise by

Therapeutic areas

Cardiology

Neurology

Pneumology

Oncology

Immuno-oncology

Allergy

Dermatology

Gastro-enterology

Analgesia/inflammation

Endocrinology

Haematology

Nephrology

A comprehensive range of preclinical models for short and long-term toxicology studies

Our animal models

John joe

Mouse

John joe

Rat

John joe

Dog

John joe

Rabbit

John joe

Marmoset

John joe

Ferret

John joe

Cynomolgus Monkeys

John joe

Guinea Pig

John joe

Cat

John joe

Hamster

John joe

MiniPig

A wide range of services that span the entire drug discovery and development continuum and can be tailored to specific research conditions

Our Services

NEED TO CREATE YOUR

UNIQUE PROJECT

Each project is managed by a study director, relying on a multi-disciplinary team of experts.